The Return of World ADC in San Diego!

ADCs are Shifting the Future of Oncology Treatment

3 years since we last brought the community together in-person in San Diego we are excited to once more unite 600+ ADC enthusiasts at the World’s Definitive Antibody-Drug Conjugate Event.

We've seen continued successes into 2022 with ImmunoGen & Byondics submitting their BLAs, Enhertu being approved in HER2-low Breast Cancer, 33 more candidates entering the clinic and ever-growing number of preclinical assets - the promise of ADCs to change the paradigm of oncology treatment is beginning to be realized. Therefore, we are looking forward to bringing the community back-in person at our biggest and best event to date to help forward thinking researchers from biopharma advance the development of and maximize the clinical therapeutic index of ADCs.

Providing you with a comprehensive roadmap to ADC success, enjoy 4 days jam-packed full of learning with 5 dedicated tracks covering the end-to-end development of ADCs, 6 seminar days providing focused conversation on understanding and overcoming challenges associated with toxicity, next-generation payloads, bioanalysis and much more! Additionally, our 120+ expert speaker faculty from companies at the forefront of ADC innovation including Daiichi Sankyo, AstraZeneca, Merck, Mersana Therapeutics, AbbVie and many more, will leave no stone left unturned to advance more life changing drugs to patients.

Capitalizing on recent successes and now with a defined regulatory pathway, there has never been this amount of excitement or promise for the ADC community, so now is your chance to keep your finger on the pulse with recent developments and look forward to the next big breakthroughs!

Your 100 + World Class Speakers Include:

Betsy Gray

Principal Scientist, Therapeutic Discovery

Seagen

Elaine Hurt

Senior Director, Bioscience

AstraZeneca

Laughing Bear Torrez

Associate Director

Bolt Biotherapeutics

Rajeev Menon

Senior Director & Senior Research Fellow

AbbVie

Ying Wang

Executive Medical Director

ADC Therapeutics

Derek Langeslay

Senior Research Scientist

Gilead

Ian Schwartz

Director, Bioconjugation Process Development

Exelixis

Marisa Schmitt

Group Leader, Bioanalytics

Heidelberg Pharma Research

Ramana Doppalapudi

Vice President, Chemistry

Avidity Biosciences

Werner Rubas

Vice President, Preclinical Development

Sutro Biopharma

About World ADC Series

The World ADC team ploughs its collective energy into sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distill this into accessible formats of information exchange – for you. From globally leading conferences, to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.

The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavors more informed and more robust.

We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.

Join us at the heart of the ADC community to improve your programs and be part of the mission to develop better antibody drug conjugate drugs.

Proud To Partner With

Senior Partners:

aj bio
nj bio
synaffix
wuxi
T3

Other Events In The Series